TriSalus Life Sciences, a Denver-area oncology company, announced a new chief financial officer. Effective July 1, David Patience will assume the role, bringing extensive capital markets expertise to the company.
TriSalus is a medtech company working to improve outcomes for patients with solid tumors. Its platform incorporates devices that use a proprietary drug delivery technology as well as clinical-stage investigational immunotherapy.
Prior to TriSalus, Patience served as CFO at Accelerate Diagnostics, spearheading product portfolio planning, market analysis and partnership feasibility analysis. He succeeds James Young, who stepped down from the role of CFO on May 30. Dan Giordano, TriSalus’s VP of finance, is serving as CFO in the meantime until Patience’s appointment.
